Despite market gains, Harbor Long-Term Growers ETF returned 6.90% (NAV) in Q3. Read the full report to understand key drivers ...
Novo Nordisk (NVO) closed the most recent trading day at $47.81, moving -2.35% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 1.16%. Meanwhile, the ...
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain ...
7h
Federal judges consolidate GLP-1 vision loss lawsuits, sends cases to federal judge in Pennsylvania
Judges allow consolidation of vision loss lawsuits filed against Novo Nordisk and Eli Lilly over diabetes and weight loss ...
On December 15, 2025, UBS reaffirmed its Neutral (Hold) rating on NVO with an unchanged price target of DKK 295, reflecting ...
In this week’s edition of InnovationRx, we look at French healthtech Doctolib’s potential large secondary round, Alice ...
Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...
GreensKeeper Asset Management, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
For one, interest rates are finally going down, with the Federal Reserve executing its latest cut on December 10. And ...
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down ...
In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...
Meanwhile, the 25-milligram dose of Novo Nordisk's oral semaglutide helped patients lose up to 16.6% of their weight on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback